스타가르트병 치료제 시장 : 약제 유형별, 투여 경로별, 유통 채널별, 최종 사용자별, 국가별, 지역별 - 업계 분석, 시장 규모, 시장 점유율 및 예측(2026-2033년)

Stargardt Disease Therapeutics market size was valued at US$ 398.7 Million in 2025, expanding at a CAGR of 30.4% from 2026 to 2033.

Stargardt disease treatments involve various pipeline therapies that include gene therapy, drug-based treatments, and cellular protective treatments that aim at reducing the effects of vision degeneration caused by ABCA4 mutations. This approach is very common within the industry and involves carrying out molecular testing to establish appropriate candidates for the therapy interventions, which include gene therapy, oral retinoid inhibitors, and cell therapy, before moving to clinical trials where there is a focus on safety aspects and visual function testing. All these clinical trials rely on retinal imaging, microperimetry, perimetry functions, and visual aids. These treatments are making headway into improving visual and patient health outcomes.

Stargardt Disease Therapeutics Market- Market Dynamics

Rising Prevalence Of Stargardt Disease To Propel Market Demand

The increasing prevalence and diagnosis of Stargardt disease are driving market growth, because one in 8,000 to 10,000 is diagnosed with Stargardt disease, and there are further diagnoses of late-onset Stargardt disease's increasing prevalence and awareness in patients, which have been raising the demand for the right kinds of treatment solutions. For instance, in May 2026, according to EyeWiki.org, 1 out of 6,578 individuals is suffering from Stargardt disease and is approximately 7.0% of all the retinal degeneration in the general population. Stargardt disease is prevalent among the European population and is also the most prevalent among all inherited retinal diseases, and awareness among the people about their disease has increased demand from various sources. This growing patient population is expected to accelerate demand for innovative Stargardt disease treatments and therapies.

Stargardt Disease Therapeutics Market- Segmentation Analysis:

The Global Stargardt Disease Therapeutics market is segmented on the basis of Drug Type, Route of Administration, Distribution Channel, End User, and Region.

Under drug type, gene therapy plays a key role in the Stargardt Disease Therapeutics market due to the involvement of genetics as the etiology of the disease. The use of gene therapy helps to rectify any gene anomalies present in the ABCA4 gene. In April 2026, Astellas Pharma Inc. developed their Stargardt-type macular dystrophy drug pipeline, ASP2020, by using allogeneic cell therapy, which will restore sight in Stargardt-type macular dystrophies by replacing retinal pigment epithelial cells. These advancements are expected to accelerate innovation and expand treatment options for Stargardt disease patients.

Stargardt Disease Therapeutics Market- Geographical Insights

North America holds the notable share of the global Stargardt Disease Therapeutics market, supported by advanced diagnostic infrastructure, highly advanced infrastructure used to diagnose the condition, and high expenditure on health, health care research, and supportive regulations for orphan drugs. For instance, in May 2026, according to Health Systems Facts (Org.), the total health expenditure in Canada was $7,300.64 (USD PPP) per capita, representing 11.30% of GDP, where government/compulsory expenditure represented 7.93% of GDP ($5,124.51 per capita), while the voluntary/out-of-pocket expenditure represented 3.37% ($2,176.14 per capita). This huge health expenditure in the region helps in making the advanced diagnosis and treatment of the disease possible in North America.

Mexico Stargardt Disease Therapeutics Market - Country Insights

Mexico has developed chances for the distribution of specialty drugs and support services that will enable the distribution of gene therapy drugs to patients, but the issue of cost and accessibility remains an obstacle. For instance, in February 2025, according to the PAN Foundation Org., more than 2,700 patients suffering from chronic illnesses and who are over 18 years of age, 22% of those patients currently using a prescription drug found it hard to pay for the prescribed drugs, while 23% could not afford their prescriptions. Also, 21% of patients said that they did not get their prescription due to the price. These challenges highlight the need for stronger financial support and patient access programs.

Stargardt Disease Therapeutics Market- Competitive Landscape:

The competitive landscape for Stargardt disease therapeutics includes large firms, both big companies and particular biotechnology companies that develop new therapies using gene therapy and disease-modifying treatments. Other competitors, which also should be taken into account, include Hoffmann-La Roche Ltd., Astellas Pharma Inc., Kubota Vision Inc., Applied Genetic Technologies Corporation (AGTC), and MeiraGTx Holdings plc, working on inherited retinal disease drugs and improving their competitive advantage through their clinical research and collaborations and gene therapy technologies. In May 2026, Kubota Vision Inc. signed an agreement with Laboratoires KOL for the supply and licensing of Emixustat for the treatment of Stargardt disease in France based on a compassionate use program, under which Kubota Vision will manufacture and supply the drug exclusively, whereas KOL will have exclusive rights to distribute the drug in France. These strategic initiatives are expected to intensify competition and accelerate innovation in Stargardt disease therapeutics.

Recent Developments:

In June 2025, SpliceBio received €119 million (US$135 million) in funding through Series B financing from EQT Life Sciences and Sanofi Ventures for its SB-007 gene therapy product for Stargardt disease, in conjunction with the ASTRA Phase 1/2 clinical trial.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL STARGARDT DISEASE THERAPEUTICS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

• AAVantgarde Bio S.r.l.
• Ascidian Therapeutics, Inc.
• Ray Therapeutics, Inc.
• Ocugen, Inc.
• Stargazer Pharmaceuticals, Inc.
• Nacuity Pharmaceuticals, Inc.
• Sepul Bio, Inc.
• PYC Therapeutics Limited
• SpliceBio
• Opus Genetics, Inc.
• Atsena Therapeutics, Inc.
• MeiraGTx Holdings plc
• Beacon Therapeutics
• Coave Therapeutics
• Saliogen Therapeutics
• Belite Bio, Inc.
• Alkeus Pharmaceuticals, Inc.
• Nanoscope Therapeutics, Inc.
• VeonGen Therapeutics
• Astellas Pharma Inc.
• Others

GLOBAL STARGARDT DISEASE THERAPEUTICS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2020 - 2033

• Gene Therapy
• Small Molecule Drugs
• Stem Cell / Cell-Based Therapy
• RNA-Based Therapy
• Others

GLOBAL STARGARDT DISEASE THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2020 - 2033

• Oral
• Intravitreal
• Subretinal
• Others

GLOBAL STARGARDT DISEASE THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2020 - 2033

• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies

GLOBAL STARGARDT DISEASE THERAPEUTICS MARKET, BY END USER- MARKET ANALYSIS, 2020 - 2033

• Hospitals
• Ophthalmology / Retina Clinics
• Specialty Eye Care Centers
• Research & Academic Institutes
• Others

GLOBAL STARGARDT DISEASE THERAPEUTICS MARKET, BY REGION- MARKET ANALYSIS, 2020 - 2033

• North America
• U.S.
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• The Netherlands
• Sweden
• Russia
• Poland
• Denmark
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• South Korea
• Australia
• Indonesia
• Thailand
• Philippines
• Taiwan
• Vietnam
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• Rest of LATAM
• The Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Turkey
• Algeria
• Egypt
• Iran
• Qatar
• Rest of MEA

Table of Contents

1. Stargardt Disease Therapeutics Market Overview

• 1.1. Study Scope
• 1.2. Market Estimation Years

2. Executive Summary

• 2.1. Market Snippet
  • 2.1.1. Stargardt Disease Therapeutics Market Snippet by Drug Type
  • 2.1.2. Stargardt Disease Therapeutics Market Snippet by Route of Administration
  • 2.1.3. Stargardt Disease Therapeutics Market Snippet by Distribution Channel
  • 2.1.4. Stargardt Disease Therapeutics Market Snippet by End User
  • 2.1.5. Stargardt Disease Therapeutics Market Snippet by Country
  • 2.1.6. Stargardt Disease Therapeutics Market Snippet by Region
• 2.2. Competitive Insights

3. Stargardt Disease Therapeutics Key Market Trends

• 3.1. Stargardt Disease Therapeutics Market Drivers
  • 3.1.1. Impact Analysis of Market Drivers
• 3.2. Stargardt Disease Therapeutics Market Restraints
  • 3.2.1. Impact Analysis of Market Restraints
• 3.3. Stargardt Disease Therapeutics Market Opportunities
• 3.4. Stargardt Disease Therapeutics Market Future Trends

4. Stargardt Disease Therapeutics Industry Study

• 4.1. PEST Analysis
• 4.2. Porter's Five Forces Analysis
• 4.3. Growth Prospect Mapping
• 4.4. Regulatory Framework Analysis

5. Stargardt Disease Therapeutics Market : Impact of Escalating Geopolitical Tensions

• 5.1. Impact of COVID-19 Pandemic
• 5.2. Impact of Russia-Ukraine War
• 5.3. Impact of Middle East Conflicts

6. Stargardt Disease Therapeutics Market Landscape

• 6.1. Stargardt Disease Therapeutics Market Share Analysis, 2025
• 6.2. Breakdown Data, by Key Manufacturer
  • 6.2.1. Established Players' Analysis
  • 6.2.2. Emerging Players' Analysis

7. Stargardt Disease Therapeutics Market - By Drug Type

• 7.1. Overview
  • 7.1.1. Segment Share Analysis, By Drug Type, 2025 & 2033 (%)
  • 7.1.2. Gene Therapy
  • 7.1.3. Small Molecule Drugs
  • 7.1.4. Stem Cell / Cell-Based Therapy
  • 7.1.5. RNA-Based Therapy
  • 7.1.6. Others

8. Stargardt Disease Therapeutics Market - By Route of Administration

• 8.1. Overview
  • 8.1.1. Segment Share Analysis, By Route of Administration, 2025 & 2033 (%)
  • 8.1.2. Oral
  • 8.1.3. Intravitreal
  • 8.1.4. Subretinal
  • 8.1.5. Others

9. Stargardt Disease Therapeutics Market - By Distribution Channel

• 9.1. Overview
  • 9.1.1. Segment Share Analysis, By Distribution Channel, 2025 & 2033 (%)
  • 9.1.2. Online Pharmacies
  • 9.1.3. Hospital Pharmacies
  • 9.1.4. Retail Pharmacies

10. Stargardt Disease Therapeutics Market - By End User

• 10.1. Overview
  • 10.1.1. Segment Share Analysis, By End User, 2025 & 2033 (%)
  • 10.1.2. Hospitals
  • 10.1.3. Ophthalmology / Retina Clinics
  • 10.1.4. Specialty Eye Care Centers
  • 10.1.5. Research & Academic Institutes
  • 10.1.6. Others

11. Stargardt Disease Therapeutics Market - By Geography

• 11.1. Introduction
  • 11.1.1. Segment Share Analysis, By Geography, 2025 & 2033 (%)
• 11.2. North America
  • 11.2.1. Overview
  • 11.2.2. Stargardt Disease Therapeutics Key Manufacturers in North America
  • 11.2.3. North America Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 11.2.4. North America Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
  • 11.2.5. North America Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 11.2.6. North America Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  • 11.2.7. North America Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.2.8. U.S.
    • 11.2.8.1. Overview
    • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.2.8.3. U.S. Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.2.8.4. U.S. Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.2.8.5. U.S. Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.2.8.6. U.S. Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.2.9. Canada
    • 11.2.9.1. Overview
    • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.2.9.3. Canada Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.2.9.4. Canada Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.2.9.5. Canada Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.2.9.6. Canada Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
• 11.3. Europe
  • 11.3.1. Overview
  • 11.3.2. Stargardt Disease Therapeutics Key Manufacturers in Europe
  • 11.3.3. Europe Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 11.3.4. Europe Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
  • 11.3.5. Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 11.3.6. Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  • 11.3.7. Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3.8. Germany
    • 11.3.8.1. Overview
    • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.8.3. Germany Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.3.8.4. Germany Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.3.8.5. Germany Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.8.6. Germany Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3.9. UK
    • 11.3.9.1. Overview
    • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.9.3. UK Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.3.9.4. UK Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.3.9.5. UK Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.9.6. UK Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3.10. France
    • 11.3.10.1. Overview
    • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.10.3. France Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.3.10.4. France Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.3.10.5. France Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.10.6. France Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3.11. Italy
    • 11.3.11.1. Overview
    • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.11.3. Italy Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.3.11.4. Italy Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.3.11.5. Italy Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.11.6. Italy Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3.12. Spain
    • 11.3.12.1. Overview
    • 11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.12.3. Spain Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.3.12.4. Spain Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.3.12.5. Spain Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.12.6. Spain Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3.13. The Netherlands
    • 11.3.13.1. Overview
    • 11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.13.3. The Netherlands Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.3.13.4. The Netherlands Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.3.13.5. The Netherlands Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.13.6. The Netherlands Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3.14. Sweden
    • 11.3.14.1. Overview
    • 11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.14.3. Sweden Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.3.14.4. Sweden Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.3.14.5. Sweden Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.14.6. Sweden Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3.15. Russia
    • 11.3.15.1. Overview
    • 11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.15.3. Russia Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.3.15.4. Russia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.3.15.5. Russia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.15.6. Russia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3.16. Poland
    • 11.3.16.1. Overview
    • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.16.3. Poland Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.3.16.4. Poland Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.3.16.5. Poland Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.16.6. Poland Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3.17. Denmark
    • 11.3.17.1. Overview
    • 11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.17.3. Poland Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.3.17.4. Denmark Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.3.17.5. Denmark Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.17.6. Denmark Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.3.18. Rest of Europe
    • 11.3.18.1. Overview
    • 11.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.3.18.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.3.18.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.3.18.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.3.18.6. Rest of the Europe Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
• 11.4. Asia Pacific (APAC)
  • 11.4.1. Overview
  • 11.4.2. Stargardt Disease Therapeutics Key Manufacturers in Asia Pacific
  • 11.4.3. APAC Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 11.4.4. APAC Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
  • 11.4.5. APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 11.4.6. APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  • 11.4.7. APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4.8. China
    • 11.4.8.1. Overview
    • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.8.3. China Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.4.8.4. China Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.4.8.5. China Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.8.6. China Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4.9. India
    • 11.4.9.1. Overview
    • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.9.3. India Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.4.9.4. India Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.4.9.5. India Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.9.6. India Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4.10. Japan
    • 11.4.10.1. Overview
    • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.10.3. Japan Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.4.10.4. Japan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.4.10.5. Japan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.10.6. Japan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4.11. South Korea
    • 11.4.11.1. Overview
    • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.11.3. South Korea Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.4.11.4. South Korea Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.4.11.5. South Korea Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.11.6. South Korea Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4.12. Australia
    • 11.4.12.1. Overview
    • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.12.3. Australia Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.4.12.4. Australia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.4.12.5. Australia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.12.6. Australia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4.13. Indonesia
    • 11.4.13.1. Overview
    • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.13.3. Indonesia Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.13.6. Indonesia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4.14. Thailand
    • 11.4.14.1. Overview
    • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.14.3. Thailand Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.4.14.4. Thailand Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.4.14.5. Thailand Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.14.6. Thailand Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4.15. Philippines
    • 11.4.15.1. Overview
    • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.15.3. Philippines Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.4.15.4. Philippines Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.4.15.5. Philippines Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.15.6. Philippines Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4.16. Taiwan
    • 11.4.16.1. Overview
    • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.16.3. Taiwan Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.4.16.4. Taiwan Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.4.16.5. Taiwan Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.16.6. Taiwan Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4.17. Vietnam
    • 11.4.17.1. Overview
    • 11.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.17.3. Vietnam Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.4.17.4. Vietnam Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.4.17.5. Vietnam Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.17.6. Vietnam Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.4.18. Rest of APAC
    • 11.4.18.1. Overview
    • 11.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.4.18.3. Rest of APAC Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.4.18.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.4.18.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.4.18.6. Rest of APAC Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
• 11.5. Latin America (LATAM)
  • 11.5.1. Overview
  • 11.5.2. Stargardt Disease Therapeutics Key Manufacturers in Latin America
  • 11.5.3. LATAM Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 11.5.4. LATAM Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
  • 11.5.5. LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 11.5.6. LATAM Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  • 11.5.7. LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.5.8. Brazil
    • 11.5.8.1. Overview
    • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.5.8.3. Brazil Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.5.8.4. Brazil Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.5.8.5. Brazil Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.5.8.6. Brazil Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.5.9. Mexico
    • 11.5.9.1. Overview
    • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.5.9.3. Mexico Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.5.9.4. Mexico Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.5.9.5. Mexico Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.5.9.6. Mexico Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.5.10. Argentina
    • 11.5.10.1. Overview
    • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.5.10.3. Argentina Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.5.10.4. Argentina Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.5.10.5. Argentina Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.5.10.6. Argentina Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.5.11. Colombia
    • 11.5.11.1. Overview
    • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.5.11.3. Colombia Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.5.11.4. Colombia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.5.11.5. Colombia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.5.11.6. Colombia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.5.12. Rest of LATAM
    • 11.5.12.1. Overview
    • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
• 11.6. Middle East and Africa (MEA)
  • 11.6.1. Overview
  • 11.6.2. Stargardt Disease Therapeutics Key Manufacturers in Middle East and Africa
  • 11.6.3. MEA Market Size and Forecast, By Country, 2020 - 2033 (US$ Million)
  • 11.6.4. MEA Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
  • 11.6.5. MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
  • 11.6.6. MEA Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
  • 11.6.7. MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6.8. Saudi Arabia
    • 11.6.8.1. Overview
    • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6.9. United Arab Emirates
    • 11.6.9.1. Overview
    • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6.10. Israel
    • 11.6.10.1. Overview
    • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.10.3. Israel Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.6.10.4. Israel Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.6.10.5. Israel Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.6.10.6. Israel Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6.11. Turkey
    • 11.6.11.1. Overview
    • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.11.3. Turkey Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.6.11.4. Turkey Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.6.11.5. Turkey Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.6.11.6. Turkey Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6.12. Algeria
    • 11.6.12.1. Overview
    • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.12.3. Algeria Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.6.12.4. Algeria Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.6.12.5. Algeria Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.6.12.6. Algeria Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6.13. Egypt
    • 11.6.13.1. Overview
    • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.13.3. Egypt Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.6.13.4. Egypt Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.6.13.5. Egypt Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.6.13.6. Egypt Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6.14. Iran
    • 11.6.14.1. Overview
    • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.14.3. Iran Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.6.14.4. Iran Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.6.14.5. Iran Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.6.14.6. Iran Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6.15. Qatar
    • 11.6.15.1. Overview
    • 11.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.15.3. Qatar Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.6.15.4. Qatar Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.6.15.5. Qatar Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.6.15.6. Qatar Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)
  • 11.6.16. Rest of MEA
    • 11.6.16.1. Overview
    • 11.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2020 - 2033, (US$ Million)
    • 11.6.16.3. Rest of MEA Market Size and Forecast, By Drug Type, 2020 - 2033 (US$ Million)
    • 11.6.16.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2020 - 2033 (US$ Million)
    • 11.6.16.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2020 - 2033 (US$ Million)
    • 11.6.16.6. Rest of MEA Market Size and Forecast, By End User, 2020 - 2033 (US$ Million)

12. Key Vendor Analysis- Stargardt Disease Therapeutics Industry

• 12.1. Competitive Benchmarking
  • 12.1.1. Competitive Dashboard
  • 12.1.2. Competitive Positioning
• 12.2. Company Profiles
  • 12.2.1. AAVantgarde Bio S.r.l.
  • 12.2.2. Ascidian Therapeutics, Inc.
  • 12.2.3. Ray Therapeutics, Inc.
  • 12.2.4. Ocugen, Inc.
  • 12.2.5. Stargazer Pharmaceuticals, Inc.
  • 12.2.6. Nacuity Pharmaceuticals, Inc.
  • 12.2.7. Sepul Bio, Inc.
  • 12.2.8. PYC Therapeutics Limited
  • 12.2.9. SpliceBio
  • 12.2.10. Opus Genetics, Inc.
  • 12.2.11. Atsena Therapeutics, Inc.
  • 12.2.12. MeiraGTx Holdings plc
  • 12.2.13. Beacon Therapeutics
  • 12.2.14. Coave Therapeutics
  • 12.2.15. Saliogen Therapeutics
  • 12.2.16. Belite Bio, Inc.
  • 12.2.17. Alkeus Pharmaceuticals, Inc.
  • 12.2.18. Nanoscope Therapeutics, Inc.
  • 12.2.19. VeonGen Therapeutics
  • 12.2.20. Astellas Pharma Inc.
  • 12.2.21. Others

13. 360 Degree AnalystView

14. Appendix

• 14.1. Research Methodology
• 14.2. References
• 14.3. Abbreviations
• 14.4. Disclaimer
• 14.5. Contact Us